Mark Erlander, PhD

Articles by Mark Erlander, PhD

KRAS and Outcomes in Pancreatic Cancer

ByMark Erlander, PhD
Published: | Updated:

Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.

Latest Updated Articles